Therapies which act on neuropeptide S receptors
View Patent ↗Compositions and methods that act on Neuropeptide S receptors (NPSR) (also known as “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness, spontaneous movement, bronchoconstriction, contraction of bronchial smooth muscle or other effects. Antagonists of the NPSR may be administered to cause decreased arousal, decreased awakening, decreased alertness, decreased spontaneous movement, sleep, somnolence, sedation, anxiolytic effects, normalized sleep patterns, normalized sleep stages, increased duration of sleep, bronchodilation, relaxation of broncheal smooth muscle or other effects.
1. A method for treating narcolepsy, hypersomnia, or anxiety in a human subject who suffers from such disorder, said method comprising the step of:
A. administering an NPSR agonist to the subject in an amount and by a route of administration that is effective to treat said disorder;
wherein the NPSR agonist comprises NPS or isolated NPS.
2. A method according to claim 1 wherein the NPSR agonist comprises isolated NPS.
3. A method according to claim 1 wherein the NPSR agonist comprises NPS which comprises the amino acid sequence Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys-Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser-OH (SEQ ID NO:1).